

Regimen Reference Order – MYEL – lenalidomide + dexamethasone

ARIA: MYEL - [lenalidomide + dex]

Planned Course: Every 28 days until disease progression or unacceptable toxicity

Indication for Use: Multiple Myeloma Transplant Ineligible – First Line Treatment

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $30 \times 10^9/L$

❖ Contact prescribing hematologist if parameters not met

Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – MYEL – lenalidomide + dexamethasone

Drug	Dose	CCMB Administration Guideline
dexamethasone	40 mg	Orally once daily with food on Days 1, 8, 15 and 22 (Self-administered at home)
lenalidomide	25 mg	Orally once daily on Days 1 to 21 , followed by 7 days off Take with or without food. Swallow whole (Self-administered at home)
lenalidomide available dosage strengths: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

Hepatitis B serology

- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

Day 1

- CBC, creatinine, calcium, albumin, random glucose, liver enzymes and TSH as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

Day 15 (required for the first 4 cycles)

- CBC as per Physician Orders

Per RevAid Program or Reddy2Assist Program– See Additional Information

- Patients of childbearing potential require β HCG according to RevAid Program/Reddy2Assist Program requirements

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
acetylsalicylic acid (ASA) enteric coated	81 mg delayed release	Orally once daily

INSTRUCTIONS FOR PATIENT

- Remind patient to take ASA (antiplatelet) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on lenalidomide

ADDITIONAL INFORMATION

- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy ***Hepatitis B Monitoring for Oncology and Hematology Patients*** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- Patients should take therapy to prevent blood clots while on lenalidomide. The majority of patients will be prescribed acetylsalicylic acid (ASA) enteric coated 81 mg once daily. Patients at high risk may be prescribed other anticoagulants instead of acetylsalicylic acid
- lenalidomide is teratogenic
- Patients of childbearing potential will require monthly pregnancy tests (β HCG) that must be done within 7 days of the next prescription fill
- Effective November 25th, 2021, all new patients starting on lenalidomide will be enrolled in Reddy2Assist Program. lenalidomide can only be given to patients who are registered and meet all conditions of Reddy2Assist Program
- Existing patients on lenalidomide (started prior to November 25th, 2021) are currently enrolled in RevAid Program and must meet all conditions of RevAid Program
- lenalidomide will be dispensed by CCMB Pharmacy